

# SCIENCE

Published by the **American Association for the Advancement of Science (AAAS)**, *Science* serves its readers as a forum for the presentation and discussion of important issues related to the advancement of science, including the presentation of minority or conflicting points of view, rather than by publishing only material on which a consensus has been reached. Accordingly, all articles published in *Science*—including editorials, news and comment, and book reviews—are signed and reflect the individual views of the authors and not official points of view adopted by the AAAS or the institutions with which the authors are affiliated.

The American Association for the Advancement of Science was founded in 1848 and incorporated in 1874. Its objectives are to further the work of scientists, to facilitate cooperation among them, to foster scientific freedom and responsibility, to improve the effectiveness of science in the promotion of human welfare, to advance education in science, and to increase public understanding and appreciation of the importance and promise of the methods of science in human progress.

## Membership/Circulation

**Director:** Michael Spinella  
**Deputy Director:** Marlene Zendell  
**Member Services:** Rebecca Dickerson, *Manager*; Mary Curry, *Supervisor*; Pat Butler, Helen Williams, Laurie Baker, *Representatives*  
**Marketing:** Dee Valencia, *Manager*; Jane Pennington, *Europe Manager*; Hilary Baar, *Associate*; Angela Mumeka, *Coordinator*  
**Research:** Renuka Chander, *Manager*  
**Business and Finance:** Jacquelyn Roberts, *Manager*; Robert Smariga, *Assistant Manager*  
**Administrative Assistant:** Nina Araujo de Kobes  
**Science Member Services**  
 Marion, Ohio: 800-347-6969;  
 Washington, DC: 202-326-6417  
**Other AAAS Programs:** 202-326-6400

## Advertising and Finance

**Associate Publisher:** Beth Rosner  
**Advertising Sales Manager:** Susan A. Meredith  
**Recruitment Advertising Manager:** Janis Crowley  
**Business Manager:** Deborah Rivera-Wienhold  
**Finance:** Randy Yi, *Senior Analyst*; Shawn Williams, *Analyst*  
**Marketing:** John Meyers, *Manager*; Allison Pritchard, *Associate*  
**Traffic Manager:** Tina Turano  
**Recruitment:** Terri Seiter, *Assistant Manager*; Pamela Sams, *Production Associate*; Debbie Cummings, Celeste Miller, Rachael Wilson, *Sales*; Charlotte Longhurst, *European Sales*  
**Reprints Manager:** Corrine Harris  
**Permissions Manager:** Lincoln Richman  
**Exhibits Coordinator:** Arlene Ennis  
**Sales Associate:** Carol Maddox

## PRODUCT ADVERTISING SALES: East Coast/E.

**Canada:** Richard Teeling, 201-904-9774, FAX 201-904-9701 • **Midwest/Southeast:** Elizabeth Mosko, 312-665-1150, FAX 312-665-2129 • **West Coast/W. Canada:** Neil Boylan, 415-673-9265, FAX 415-673-9267 • **UK, Scandinavia, France, Italy, Belgium, Netherlands:** Andrew Davies, (44) 1-457-838-519, FAX (44) 1-457-838-898 • **Germany/Switzerland/Austria:** Tracey Peers, (44) 1-270-760-108, FAX (44) 1-270-759-597 • **Japan:** Mashy Yoshikawa, (3) 3235-5961, FAX (3) 3235-5852

**RECRUITMENT ADVERTISING SALES: US:** 202-326-6555, FAX 202-682-0816 • **Europe:** Gordon Clark, (44) 1-81539-5211, FAX (44) 1223-302068 • **Australia/New Zealand:** Keith Sandell, (61) 02-922-2977, FAX (61) 02-922-1100

Send materials to *Science* Advertising, 1333 H Street, NW, Washington, DC 20005.

**Information for Contributors** appears on pages 112–114 of the 6 January 1995 issue. Editorial correspondence, including requests for permission to reprint and reprint orders, should be sent to 1333 H Street, NW, Washington, DC 20005.

**Internet addresses:** science\_editors@aaas.org (for general editorial queries); science\_letters@aaas.org (for letters to the editor); science\_reviews@aaas.org (for returning manuscript reviews); membership@aaas.org (for member services); science\_classifieds@aaas.org (for submitting classified advertisements)

# LETTERS

## Guidelines for Xenotransplantation

In the ScienceScope item "FDA airs qualms over xenotransplants" (6 Jan., p. 19), it was stated that the U.S. Food and Drug Administration (FDA) is concerned that "Xenografts" might allow dangerous pathogens lurking in animals to jump to humans." Readers might assume that Institutional Review Boards (IRBs) and Institutional Animal Care and Use Committees (IACUCs)



ALFRED B. THOMAS/ANIMALS, ANIMALS

**Organ donor?** Concerns about potential risks of animal-to-human transplants being addressed at medical centers.

at universities are not paying enough attention to this issue. This is not the case. For example, we at the Columbia-Presbyterian Medical Center in New York City are committed to conducting a thorough review of this possibility.

As noted in the ScienceScope item, surgeons at our institution have requested permission from the IRB and the IACUC to transplant a baboon heart into a human as a life support measure until a human heart becomes available. After initial review, many issues arose that were discussed with the investigator, including possible infectious disease consequences. A half-day workshop was held by the two committees to which the investigative group and several outside experts in various disciplines were invited. Again, the infectious disease issue and the possibility of a threat to the public health received close scrutiny. Thus, an extensive initial review of the protocols was conducted.

Several experts in infectious diseases from outside the institution were consulted who expressed a range of opinions. There are little data on the possibility of a

new infectious agent arising from xenotransplantation and, hence, there is a wide range of opinion on the probability of such an occurrence and its potential danger. Therefore, our institution has recommended that a group of experts on recurrent and emerging infections be convened to help decide this issue. The Institute of Medicine will hold a workshop to attempt to develop an acceptable protocol for minimizing the possibility of an emerging infection. The findings of the workshop could act as a guide for us and for other institutions interested in clinical xenotransplantation and for agencies such as the U.S. Centers for Disease Control and Prevention, the National Institutes of Health, and the FDA, should they decide to proceed with xenotransplantation.

**Ralph B. Dell\***

**Donald S. Kornfeld†**

*College of Physicians and Surgeons  
 of Columbia University,  
 630 West 168th Street,  
 New York, NY 10032, USA*

\*Chair, Institutional Animal Care and Use Committee, Columbia University Health Sciences. †Chair, Institutional Review Board, Columbia Presbyterian Medical Center.

## U.S. Neutron Sources

In the article "The looming neutron gap" (News & Comment, 17 Feb., p. 952), Daniel Clery and Andrew Lawler discuss the consequences of the cancellation of the Advanced Neutron Source (ANS) for neutron-scattering research in the United States. I have been a strong supporter of the ANS and agree that cancellation of the project will prevent the United States from taking the lead in this important field. However, the analysis presented was incomplete because the most productive, cost-effective U.S. neutron source is not mentioned. The research reactor at the National Institute of Standards and Technology (NIST) is in the final stages of completion of a major enhancement to its capabilities, the Cold Neutron Research Facility. The combined neutron facilities at NIST serve many more researchers than does any neutron facility at the Department of Energy (DOE), with nearly 1200 participants from 48 industries and 85 universities in the United States (and from many non-U.S. institutions). The array of instruments,

when fully operational, will approach the versatility represented at the Institut Laue-Langevin in Grenoble, France, with performance at least comparable to that of the best European reactor facilities.

None of this, of course, changes the fact that the United States must proceed to build next-generation neutron sources, and enhance existing sources where possible to meet growing needs. While construction of a new source is primarily the responsibility of DOE, we at NIST will continue to support this effort in the future as we have in the past. We will also continue to provide the best possible neutron facilities for U.S. researchers here at NIST well into the next century.

**J. Michael Rowe**

Reactor Radiation Division,  
National Institute of Standards  
and Technology,  
Gaithersburg, MD 20899-0001, USA

Clery and Lawler conclude, "But until the next century, U.S. researchers will have to traipse across the Atlantic to conduct their experiments at the world's cutting-edge neutron-scattering facilities." Neutron scattering is not an end in itself, but merely one technique used to characterize substances. To do cutting-edge neutron-scattering re-

search, one probably has to use a cutting-edge neutron-scattering facility. However, other research fields, such as materials science or biology, that use neutron scattering have other options available for cutting-edge research. The hoped for Advanced Neutron Source (ANS) in the United States was designed for neutron radiation effects research and neutron-induced production of transplutonium elements for research, in addition to neutron-scattering research. Although the design driver in the ANS was neutron-scattering experimentation, design compromises were made to accommodate the other research areas. So comments in the article about the drawbacks of dual-use facilities may have been overstatements, even though there are indeed problems with facilities that have more than one constituency.

Neutrons used in research can sometimes be replaced by probes of other types or other characterization techniques. Although neutrons provide a powerful method with which to obtain measurements of certain characteristics of materials, chemicals, and substances, it is possible to obtain proper characterization using other techniques. There is no doubt that the ANS or another powerful neutron source for the United States would be extremely useful. It appears that a win-

dow of opportunity for such a facility was missed by the previous Congresses, and preparation should be made for the next opportunity. Given the present budgetary situation and other factors, one may have to temporarily focus on improvements to existing facilities, alternative techniques, or advances in instrumentation to increase the effective neutron flux at the sample. If too much emphasis is placed on a neutron-scattering gap rather than on research advances, wrong policies or priorities, such as eliminating other research to accommodate neutron-scattering facilities, may result. The resulting harm would encompass the neutron-scattering research community as well as the remaining research fields.

**Louis Ianniello**

20006 Holly Pond Way,  
Gaithersburg, MD 20879, USA

## AIDS Data

In a set of letters entitled "AIDS-associated Kaposi's sarcoma" (24 Feb., p. 1078), there is one by Michael S. Ascher *et al.* (p. 1080) in which my letter in *Science* of 20 January (p. 313) is discussed. Ascher *et al.* write that "Duesberg misrepresents data from the San

You've probably made a few generalizations about us Swedes—that's alright, we can take them. But making assumptions about the accuracy of your automated DNA sequencer can be costly. So demand proof.

ALFexpress™ provides you with speed, affordability and ease of use in giving you the highest accuracy from any automated DNA sequencer. More importantly, you can prove the accuracy of your data while your sequencer is in operation—and you can do it by yourself. How?

Let's start with the proof. ALFexpress lets you display called bases of both raw and processed data. Viewing raw data provides you with immediate visual confirmation of ALFexpress's reading accuracy—a must in demanding applications such as heterozygous detection.

Using single dye chemistry, ALFexpress eliminates spectral overlap and filtering problems and heightens the signal-to-noise ratio. Equipped with an outstanding base calling algorithm, you get accurate and reliable results. So with ALFexpress pumping

out clean, clear data you can check, you reduce operation time.

By generating 300 base pairs of accurate sequenced data in about an hour, you gain the type of speed that's difficult to match. As high-speed separations are equally important in fragment analysis, you can also separate between 150 and 200 base pairs in about 30 minutes on ALFexpress. Offering more than just sheer speed and accuracy, ALFexpress provides you with easy operating and working methods.

So easy that after only a two-hour introduction, six out of eight people with good lab experience—who had never used an automated DNA sequencer—got the kind of results that begin to prove this important point: you won't need a supervising technician in your lab with ALFexpress. And that was just the first test.

Why not arrange to take your own? To start, just call us at 1 (800) 526 3593 in North America, or +46 18 16 5011 from the rest of the world; and ask for a brochure. It will give you more facts about the entire ALFexpress package. That's right, facts—because the last thing anyone needs is more inaccurate documents.